RxDoctor Payments Data

Irfan Siddiqui, MD

Interventional Cardiology · Newburgh, INNPI 1871913046

Payments from drug & device makers

$3,762in general payments, 2019–2025

Across 56 payments — averaging $67.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$2K
  • Biotronik Inc.$441
  • Medtronic$270
  • Boston Scientific$254
  • Abiomed$167
  • Cardiovascular Systems Inc.$133
  • plus $504 from 10 others

What the payments were for

  • Travel & lodging$1,48039%
  • Food & beverage$2,28261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,762 in reported general payments places this provider in the 30th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$197,104
Medicare patients
1,568
Services billed
2,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$145,852
EntrestoSacubitril/Valsartan56$59,356
Repatha SureclickEvolocumab32$38,932
FarxigaDapagliflozin Propanediol30$37,490
XareltoRivaroxaban26$28,554
BrilintaTicagrelor24$14,344
Praluent PenAlirocumab20$11,658
Ranolazine ErRanolazine40$6,255
Metoprolol Succinate306$3,446
Isosorbide Mononitrate ErIsosorbide Mononitrate166$2,176
Atorvastatin Calcium268$2,088
Midodrine Hcl22$1,680
Amlodipine Besylate259$1,605
Hydralazine Hcl34$1,413
Ezetimibe46$1,388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$20$51,83454 claims
Johnson & JohnsonXarelto$31$28,55426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →